2-[[(3R)-piperidin-3-yl]methyl]isoindole-1,3-dione | 1000592-62-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[[(3R)-piperidin-3-yl]methyl]isoindole-1,3-dione
• CAS: 1000592-62-0
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: BDHKFLLJZKAXII-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[[(3R)-piperidin-3-yl]methyl]isoindole-1,3-dione 、 4-异丁基苯甲醛 在 三乙酰氧基硼氢化钠 作用下， 生成
  参考文献：
  名称：

  N-Benzyl-3-sulfonamidopyrrolidines as novel inhibitors of cell division in E. coli

  摘要：

  A new small molecule inhibitor of bacterial cell division has been discovered using a high-throughput screen in Escherichia coli. Although the lead screening hit (534F6) exhibited modest inhibition of the GTPase activity of FtsZ (20 +/- 5% at 100 mu M of compound), a primary target for bacterial cell division inhibitors, several analogs caused potent bacterial growth inhibition with negligible antagonism of FtsZ GTPase activity. A library of analogs has been prepared and several alkyne-tagged photo-affinity probes have been synthesized for use in experiments to elucidate the primary target of this compound. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.010

文献信息

• PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP4083038A1

  公开（公告）日：2022-11-02

  A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody / anti-PD-Ll antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody / anti-PD-Ll antibody therapy, and found that a pyridazinyl-thiazolecarboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The pyridazinyl-thiazolecarboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody / anti-PD-Ll antibody therapy.

  本发明提供了一种可作为药物组合物活性成分的化合物，该药物组合物可用于治疗与免疫细胞活化相关的癌症或对抗癌多肽-1 抗体/抗癌多肽-Ll 抗体治疗具有抗药性的癌症。 本发明人对一种可作为药物组合物活性成分的化合物进行了研究，该药物组合物可用于治疗与免疫细胞活化相关的癌症或对抗朴-PD-1抗体/抗朴-PD-Ll抗体治疗具有抗药性的癌症，并发现一种哒嗪基噻唑甲酰胺化合物具有DGKξ（DGKzeta）抑制作用，从而完成了本发明。本发明的哒嗪基噻唑甲酰胺化合物具有DGKξ抑制作用，可作为治疗剂用于治疗与免疫细胞活化相关的癌症或抗PD-1抗体/抗PD-Ll抗体治疗耐药的癌症。
• PYRIDAZINYL-THIAZOLECARBOXAMIDE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20220315603A1

  公开（公告）日：2022-10-06

  A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and found that a pyridazinyl-thiazolecarboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The pyridazinyl-thiazolecarboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy.
• [EN] PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND<br/>[FR] COMPOSÉ PYRIDAZINYL THIAZOLECARBOXAMIDE<br/>[JA] ピリダジニルチアアゾールカルボキシアミド化合物
  申请人：ASTELLAS PHARMA INC

  公开号：WO2021132422A1

  公开（公告）日：2021-07-01

  免疫細胞活性化に関連するがん、又は、抗PD-1抗体/抗PD-L1抗体療法に耐性を有するがんの治療用医薬組成物の有効成分として有用な化合物を提供する。 本発明者らは、免疫細胞活性化に関連するがん、又は、抗PD-1抗体/抗PD-L1抗体療法に耐性を有するがんの治療用医薬組成物の有効成分として有用な化合物について検討し、ピリダジニルチアアゾールカルボキシアミド化合物がDGKζ(DGKzeta)阻害作用を有することを確認し、本発明を完成した。本発明のピリダジニルチアアゾールカルボキシアミド化合物はDGKζ阻害作用を有し、免疫細胞活性化に関連するがん、又は、抗PD-1抗体/抗PD-L1抗体療法に耐性を有するがんの治療剤として使用しうる。